The Effects of Simvastatin on Expression of Matrix Metalloproteinase and Inflammatory Factors in COPD Rats_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

XiongPing ¹ ,  HuangYanming ¹ , ZuoWanli ¹ , ZhangChunlai ¹ , ZhouWei ²

1. Department of Respiratory Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, 529030, China;
2. ;

Corresponding author：

HuangYanming, Email: huangyanmings@126.com

Keywords：

Chronic obstructive pulmonary disease; Matrix metalloproteinase; Inflammatory factors; Simvastatin

DOI：

10.7507/1671-6205.2015133

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the effects of simvastatin on the expression of matrix metalloproteinase (MMP) and inflammatory factors in rats with smoke-induced chronic obstructive pulmonary disease (COPD). Methods 40 male Wistar rats were randomly divided into four groups, including a normal group (group A), a simvastatin group (group B), a COPD model group (group C) and a simvastatin intervention group (group D). The COPD model of the group C and D were induced through exposing to the cigarette smoke repeatedly. At the same time, the rats of group B and D were given by gavage 5 mg/(kg·d) with simvastatin, and the other two groups were given with the same volume saline for 16 weeks. Pulmonary function tests and pathological examination of the lung tissue were performed after the induction of COPD model. Enzyme-linked immunosorbent assay (ELISA) method was used to measure the content of MMP-2, MMP-9, IL-6, IL-8, TNF-α in lung tissue homogenate. Results The airway resistance of group C and group D was significantly higher than the group A and group B (P<0.01), and the airway resistance of group D was significantly lower than group C (P<0.01). The degree of bronchial inflammation and emphysema of group C was more apparent than group D in the pathological section, and there were no bronchial inflammation and emphysema in group A and group B. The ELISA results showed that the contents of MMP-2, MMP-9, IL-6, IL-8, TNF-α in group C were all significantly higher than those in group D. Conclusion Simvastatin has inhibitory effect on pulmonary inflammation of COPD, and can reduce the expression of matrix metalloproteinase and inflammatory factors in the lung.

Citation： XiongPing, HuangYanming, ZuoWanli, ZhangChunlai, ZhouWei. The Effects of Simvastatin on Expression of Matrix Metalloproteinase and Inflammatory Factors in COPD Rats. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(6): 541-545. doi: 10.7507/1671-6205.2015133 Copy

1.	Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med,2007,176:532-555.
2.	宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重塑及生长因子的研究.中华结核和呼吸杂志,2001,24:283-287.
3.	Larsson K. Inflammatory markers in COPD. Clin Respir J,2008,2 Suppl 1:84-87.
4.	Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med,1996,153:530-534.
5.	Kuschner WG, D'Alessandro A, Wong H, et al. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J,1996,9:1989-1994.
6.	Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet,2011,378:1015-1026.
7.	Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax,2006,61:259-266.
8.	Omachi TA, Eisner MD, Rames A, et al. Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respir Res,2011,12:35.
9.	Culpitt SV, Rogers DF, Traves SL, et al. Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med,2005,99:703-710.
10.	Louhelainen N, Stark H, Mazur W, et al. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation:a research study. BMC Pulm Med,2010,10:13.
11.	Navratilova Z, Zatloukal J, Kriegova E, et al. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology,2012,17:1006-1012.
12.	Hothersall EC, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax,2006,61:729-734.
13.	Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med,2011,183:50-58.

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med,2007,176:532-555.
2. 宋一平,崔德健,茅培英,等.慢性阻塞性肺疾病大鼠模型气道重塑及生长因子的研究.中华结核和呼吸杂志,2001,24:283-287.
3. Larsson K. Inflammatory markers in COPD. Clin Respir J,2008,2 Suppl 1:84-87.
4. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med,1996,153:530-534.
5. Kuschner WG, D'Alessandro A, Wong H, et al. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J,1996,9:1989-1994.
6. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet,2011,378:1015-1026.
7. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax,2006,61:259-266.
8. Omachi TA, Eisner MD, Rames A, et al. Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respir Res,2011,12:35.
9. Culpitt SV, Rogers DF, Traves SL, et al. Sputum matrix metalloproteases:comparison between chronic obstructive pulmonary disease and asthma. Respir Med,2005,99:703-710.
10. Louhelainen N, Stark H, Mazur W, et al. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation:a research study. BMC Pulm Med,2010,10:13.
11. Navratilova Z, Zatloukal J, Kriegova E, et al. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology,2012,17:1006-1012.
12. Hothersall EC, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax,2006,61:729-734.
13. Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med,2011,183:50-58.

Previous Article
Role of Autophagy-lysosomal System in Skeletal Muscle Atrophy in COPD Rats
Next Article
The Relationship of Obesity with Asthma Control and Airway Inflammatory Phenotype

Chinese Journal of Respiratory and Critical Care Medicine

The Effects of Simvastatin on Expression of Matrix Metalloproteinase and Inflammatory Factors in COPD Rats

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content